Login
Companies $PMN
$3.25 -$0.06 (1.81%) After hours
ProMIS Neurosciences Inc. logo

ProMIS Neurosciences Inc.

promisneurosciences.com

What Do They Do?

Develops antibody therapies and therapeutic vaccines aimed at misfolded proteins linked to neurodegenerative and other protein-misfolding diseases, and plans to license successful products to pharmaceutical partners.

Who Are Their Customers?

ProMIS plans to license products to pharmaceutical companies or form strategic alliances with them. Partners may fund development and, if a product reaches market, use their manufacturing and distribution networks.

How Are They Changing?

Parkinson’s disease The older report described Parkinson’s disease as a possible additional area; the latest includes it among the diseases its antibody pipeline targets.

Who Do They Compete With?

Competes with Alzheon, Alzinova, Chugai Pharmaceutical, Cognition Therapeutics, Eisai, Eli Lilly and, Grifols, KalGene Pharmaceuticals, Neurimmune, Novartis, Acumen Pharmaceuticals, Prothena Biosciences, Roche Holding, Wren Therapeutics, AbbVie, AC Immune, Alector, Anavex Life Sciences, Annovis Bio, and Athira Pharma

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support